Profound Medical Corp.

TSX:PRN.TO

Medical - Devices

Healthcare
$9.83 +1.18%

+$0.11 today

Market cap
$360.04M
Beta
0.52
P/E (TTM)
-6.3
EPS (TTM)
-$1.07
52W Low $5.23High $12.40

Volume 0.00M

Average 0.01M

PRN.TO Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Profound Medical Corp.TSX: PRN.TO

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow turns positive

Q1 FY2026 financing cash flow was $0, compared with -$290K a year earlier. Trailing-twelve-month financing cash flow was $42.16M. Over 3 fiscal years it compounded at +81.2% a year.

Context

  • Financing cash flow amounted to 255.5% of revenue in FY2025, down 256.6 pp from a year earlier.
  • Financing cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly financing cash flow holds near $0 or moves back toward the trailing-twelve-month quarterly average of $10.54M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$41.86M-23.5% YoY
LTMMar 2026
$42.16M+23.9% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year-23.5%——
3-year CAGR+81.2%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
41.86M USD
Year-over-year change
-23.5%
4-year CAGR
+62.9%

Financing Cash Flow vs competitors

How PRN.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +23.9% is the 2nd highest of 6, against a peer median of -42.1%.
  • Financing cash flow amounts to 224.7% of revenue for PRN.TO, versus a peer median of 13.3%.
PRN.TO Competitors
Financing Cash Flow for PRN.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$122.16M USD+399.3%+78.9%—
DR.TOMedical Facilities CorporationLTM Mar 2026$67.77M USD-43.9%+11.5%22.2%
PRN.TOProfound Medical Corp.LTM Mar 2026$42.16M USD+23.9%+81.2%224.7%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$23.36M USD-1.0%+44.1%41.9%
CRRX.TOCareRx CorporationLTM Mar 2026CA$16.16M CAD-42.1%+3.6%4.3%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$6.97M CAD-57.6%—4.4%
Peer median (excluding PRN.TO) —-42.1%+27.8%13.3%

Competitors are the stored peer set for PRN.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(30.7M)(28.67M)(28.32M)(27.82M)(42.57M)
Depreciation & Amortization1.88M1.6M1.15M936K569.8K
Deferred Income Tax(293K)0232K00
Stock-Based Compensation7.21M4.24M3.42M2.58M5.49M
Change in Working Capital(877K)(5.63M)540K591K(1.74M)
Accounts Receivables2M(1.93M)(1.41M)186K(175.01K)
Inventory(2.49M)(1.86M)353K656K(2.87M)
Accounts Payables(356K)(566K)1.36M815K384.62K
Other Working Capital(26K)(1.27M)244K(1.07M)918.81K
Other Non-Cash Items425K2.66M379K255K(622.65K)
Operating Cash Flow(22.36M)(25.8M)(22.61M)(23.45M)(38.88M)
Capital Expenditures(593K)000(179.08K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(583.04K)000(246.24K)
Debt Repayment(386K)6.92M(1.2M)(2.56M)(1.33M)
Common Stock Issued6.32M255.17K2.71M62.11M43.19M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities9.03K(141.17K)248.74K(4.85M)0
Financing Cash Flow5.95M7.03M1.76M54.7M41.86M
Effect of Forex Changes244K(1.87M)549K(2.54M)(630.95K)
Net Change in Cash(16.76M)(20.64M)(20.3M)28.7M2.11M
Free Cash Flow(22.95M)(25.8M)(22.3M)(23.45M)(39.05M)

Profound Medical Corp.

TSX:PRN.TO

Intrinsic Alpha fair value

Locked

Current Price

$9.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.